Compare GSK plc (GSK) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Jumia Technologies AG - ADR — how do they compare? GSK plc trades at $52.67 (market cap $101.34B), while Jumia Technologies AG - ADR trades at $6.65 (market cap $848.39M). The key difference: GSK plc is far larger — about 119.4× Jumia Technologies AG - ADR's market cap, and GSK plc pays a 3.49% dividend while Jumia Technologies AG - ADR pays none. Which is the better fit depends on your goals.
| GSK | JMIA | |
|---|---|---|
Market Cap | $101.34B | $848.39M |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $14.60 |
52-Week Low | $36.20 | $4.45 |
Enterprise Value | $121.95B | $795.49M |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
JMIA trades at $6.85, up 2.09% today, but maintains a bearish technical outlook with negative moving averages. The company shows improving fundamentals with revenue growth to $189M in 2025 and narrowing losses, though still unprofitable with a -30.79% net margin. Recent Q1 2026 results showed 39% revenue growth and progress toward 2027 profitability targets. Analyst sentiment remains positive with 71% buy ratings despite recent earnings misses.
JMIA presents a high-risk growth opportunity with improving operational metrics but persistent losses. The path to profitability by 2027 and African e-commerce expansion offer upside potential, while execution risks and competitive pressures remain key concerns. Current valuation at 4.17x sales appears reasonable for the growth trajectory if profitability targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
